In accordance, ICC with anti-C/EBPa and anti-Pparr antibodies showed no discernable differences between the β-catenin–p53–Tm+ and β-catenin–Tm+ MPCs (Fig. 5D). This evidence concerns the gene TP53 and intrahepatic cholangiocarcinoma.